Related Experiment Video

Updated: Jul 10, 2026

A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology
05:51

A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology

Published on: May 6, 2014

Anti-inflammatory drugs and atherosclerosis

Sami P Moubayed1, Therese M Heinonen, Jean-Claude Tardif

  • 1Department of Medicine, Montreal Heart Institute and Université de Montréal, Montreal, Quebec, Canada.

Current Opinion in Lipidology
|November 13, 2007
PubMed
Abstract

Insights

Inflammation plays a key role in atherosclerosis. This review examines how anti-inflammatory drugs impact atherosclerosis, with some showing promise and others disappointing results in cardiovascular disease.

Area of Science:

  • Cardiovascular Medicine
  • Inflammation Research
  • Pharmacology

Background:

  • Inflammation is a critical factor in the development and progression of atherosclerosis.
  • Understanding the inflammation-atherosclerosis link is crucial for developing effective treatments.

Purpose of the Study:

  • To review the mechanisms connecting inflammation and atherosclerosis.
  • To evaluate the impact of anti-inflammatory therapies on atherosclerotic disease.
  • To explore potential therapeutic targets and agents for atherosclerosis.

Main Methods:

  • Literature review of existing research on inflammation and atherosclerosis.
  • Analysis of studies evaluating anti-inflammatory drugs in atherosclerotic disease.
  • Examination of ongoing clinical trials and animal models for novel therapies.

Main Results:

  • Some anti-inflammatory agents show benefits for atherosclerosis and cardiovascular events, while others have yielded disappointing outcomes.
  • Statins' anti-inflammatory effects are associated with improved atherosclerosis progression and clinical results.
  • Cyclooxygenase-2 (COX-2) inhibitors' cardiovascular safety is under prospective evaluation in atherosclerosis patients.
  • Novel therapeutic agents targeting inflammatory pathways and oxidative stress are in preclinical and clinical development.

Conclusions:

  • Ongoing evaluation of existing and novel anti-inflammatory agents is vital for cardiovascular disease management.
  • Enhanced understanding of atherosclerosis and its inflammatory drivers will inform future strategies to reduce atherosclerotic cardiovascular disease incidence.

More Related Videos

Induction of Atherosclerotic Plaques Through Activation of Mineralocorticoid Receptors in Apolipoprotein E-deficient Mice07:36

Induction of Atherosclerotic Plaques Through Activation of Mineralocorticoid Receptors in Apolipoprotein E-deficient Mice

Published on: September 26, 2018

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Inflammation01:38

Inflammation

Overview
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...